Study of EPN-701 for the Treatment of Calciphylaxis

Calciphylaxis is a rare but serious condition that leads to painful skin lesions. At present, there is no approved treatment for calciphylaxis. This research study is planned to examine the potential benefits of a new treatment (EPN-701) in patients with calciphylaxis. The present early clinical study will also evaluate the pharmacology of EPN-701 and whether it can be safely used in patients with calciphylaxis. Findings will inform the planning of a future definitive study to establish EPN-701 as an approved treatment for calciphylaxis.

NCT Number	NCT07583745
Lead Sponsor	Sagar U. Nigwekar, MD, MMSc Collaborators: Epizon Pharma, Inc.
Conditions	Calciphylaxis
Enrollment	60 participants
Start Date	2026-07-01
Primary Completion	2030-06-30 (estimated)
Study Completion	2030-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-29